Literature DB >> 18601929

The influence of CRF and alpha-helical CRF(9-41) on rat fear responses, c-Fos and CRF expression, and concentration of amino acids in brain structures.

Anna Skórzewska1, Andrzej Bidziński, Adam Hamed, Małgorzata Lehner, Danuta Turzyńska, Alicja Sobolewska, Piotr Maciejak, Janusz Szyndler, Aleksandra Wisłowska-Stanek, Adam Płaźnik.   

Abstract

In the present study we have examined the influence of intracerebroventricullary administered CRF, and a non-selective CRF receptor antagonist, alpha-helical CRF((9-41)), on rat conditioned fear response, serum corticosterone, c-Fos and CRF expression, and concentration of amino acids (in vitro), in several brain structures. Pretreatment of rats with CRF in a dose of 1 microg/rat, enhanced rat-freezing response, and further increased conditioned fear-elevated concentration of serum corticosterone. Moreover, exogenous CRF increased aversive context-induced expression of c-Fos in the parvocellular neurons of the paraventricular hypothalamic nucleus (pPVN), CA1 area of the hippocampus, and M1 area of the frontal cortex. A different pattern of behavioral and biochemical changes was present after pre-test administration of alpha-helical CRF((9-41)) (10 microg/rat): a decrease in rat fear response and serum corticosterone concentration; an attenuation of fear-induced c-Fos expression in the dentate gyrus, CA1, Cg1, Cg2, and M1 areas of the frontal cortex; a complete reversal of the rise in the number of CRF immunoreactive complexes in the M2 cortical area, induced by conditioned fear. Moreover, alpha-helical CRF((9-41)) increased the concentration of GABA in the amygdala of fear-conditioned rats. Altogether, the present data confirm and extend previous data on the integrative role of CRF in the central, anxiety-related, behavioral and biochemical processes. The obtained results underline also the role of frontal cortex and amygdala in mediating the effects of CRF on the conditioned fear response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18601929     DOI: 10.1016/j.yhbeh.2008.06.002

Source DB:  PubMed          Journal:  Horm Behav        ISSN: 0018-506X            Impact factor:   3.587


  6 in total

1.  Corticotropin-releasing factor modulation of forebrain GABAergic transmission has a pivotal role in the expression of anabolic steroid-induced anxiety in the female mouse.

Authors:  Joseph G Oberlander; Leslie P Henderson
Journal:  Neuropsychopharmacology       Date:  2012-02-01       Impact factor: 7.853

2.  Enduring neurobehavioral effects of early life trauma mediated through learning and corticosterone suppression.

Authors:  Stephanie Moriceau; Charlis Raineki; Jennifer D Holman; Jason G Holman; Regina M Sullivan
Journal:  Front Behav Neurosci       Date:  2009-09-01       Impact factor: 3.558

3.  Effect of pharmacological manipulations of neuropeptide Y and corticotropin-releasing factor neurotransmission on incubation of conditioned fear.

Authors:  C L Pickens; T Adams-Deutsch; S G Nair; B M Navarre; M Heilig; Y Shaham
Journal:  Neuroscience       Date:  2009-10-02       Impact factor: 3.590

4.  Deletion of CRH From GABAergic Forebrain Neurons Promotes Stress Resilience and Dampens Stress-Induced Changes in Neuronal Activity.

Authors:  Nina Dedic; Claudia Kühne; Karina S Gomes; Jakob Hartmann; Kerry J Ressler; Mathias V Schmidt; Jan M Deussing
Journal:  Front Neurosci       Date:  2019-09-20       Impact factor: 4.677

5.  Gq Protein-Coupled Membrane-Initiated Estrogen Signaling Rapidly Excites Corticotropin-Releasing Hormone Neurons in the Hypothalamic Paraventricular Nucleus in Female Mice.

Authors:  Pu Hu; Ji Liu; Ali Yasrebi; Juliet D Gotthardt; Nicholas T Bello; Zhiping P Pang; Troy A Roepke
Journal:  Endocrinology       Date:  2016-07-07       Impact factor: 4.736

6.  Corticotropin-releasing factor induces functional and structural synaptic remodelling in acute stress.

Authors:  Dorien Vandael; Keimpe Wierda; Katlijn Vints; Pieter Baatsen; Lies De Groef; Lieve Moons; Vasily Rybakin; Natalia V Gounko
Journal:  Transl Psychiatry       Date:  2021-07-07       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.